Refractory IHCA and OHCA Treated With ECMO (SEAC)
Recruitment status was Recruiting
Extracorporeal membrane oxygenation (ECMO) support has been suggested to improve the survival rate in patients with refractory cardiac arrest (CA). Recent studies have also highlighted the potential early application of this method in improving the prognosis of prolonged cardiac arrest both for in hospital CA (INHCA) and out of hospital CA (OHCA). The rationale for use of ECMO in these patients is to optimize early perfusion of vital organs, curing the cause of CA and waiting for the recovery of the injured myocardium. The investigators have created a flow-chart to decide which patients are eligible. The aims of this study are to evaluate if, with this flow-chart, the investigators are able to detect which patients have more probability of survival.
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Official Title:||Refractory In and Out of Hospital Cardiac Arrest Treated With Extracorporeal Membrane Oxygenation. Observational, Single Centre, Prospective Study.|
- 28 days survival [ Time Frame: 28 days ] [ Designated as safety issue: No ]
- Neurologic recovery [ Time Frame: 28 days ] [ Designated as safety issue: No ]Neurologic recovery defined as minimal neurologic impairment according to the Glasgow-Pittsburgh cerebral performance categories score ≤ 2.
- Cardiac recovery [ Time Frame: 28 days ] [ Designated as safety issue: No ]Measured by echocardiography
- Six months survival with minimal neurologic impairment [ Time Frame: 180 days ] [ Designated as safety issue: No ]survival with minimal neurologic impairment according to the Glasgow-Pittsburgh cerebral performance categories score ≤ 2.
|Study Start Date:||July 2011|
|Estimated Study Completion Date:||July 2013|
|Estimated Primary Completion Date:||July 2012 (Final data collection date for primary outcome measure)|
Extracorporeal Membrane Oxygenation
All patients have to start ECMO under CPR, by insertion of peripheral VA cannulas.
Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
Please refer to this study by its ClinicalTrials.gov identifier: NCT01298050
|San Gerardo Hospital||Recruiting|
|Monza, MB, Italy, 20052|
|Contact: Leonello Avalli, MD 0039392334330 email@example.com|
|Contact: Roberto Fumagalli, MD 0039392339294 firstname.lastname@example.org|
|Principal Investigator: Leonello Avalli, MD|
|Principal Investigator:||Leonelllo Avalli, MD||Ospedale San Gerardo|